{
    "Project Title": "Apalutamide in Active Surveillance patients",
    "Sponsor": "Janssen Scientific Affairs, LLC",
    "Study Number": "9582",
    "Protocol Version and Date": "6.0; September 06, 2019",
    "Study Title": "Apalutamide in Active Surveillance patients",
    "Phase": "Phase II",
    "Therapeutic Area": "Prostate Cancer",
    "Number of Patients (if known)": "Up to 33",
    "Number of Sites (if known)": "University of Washington Medical Center",
    "Indication": "Very low-risk to low-intermediate risk prostate cancer",
    "Duration of Treatment": "90 days",
    "Schedule of Assessments": "Table 1; Section 5.3",
    "questionnaires": [
        {
            "longName": "Functional Assessment of Cancer Therapy - Prostate",
            "shortName": "FACT-P",
            "type": "PRO",
            "questionnaireSchedule": "Days 1, 180, 365, 545, 730"
        },
        {
            "longName": "Short Form Health Survey",
            "shortName": "SF-36",
            "type": "PRO",
            "questionnaireSchedule": "Days 1, 180, 365, 545, 730"
        }
    ]
}